Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

CDC), an estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom 2.7 million are chronically infected. It is estimated that there are 170 million people worldwide afflicted with this disease. While currently available therapies can cure many patients, there is considerable need for the development of novel therapeutic approaches. The HCV NS3/4 protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as ITMN-191, represent a promising new class of drugs for HCV.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 in Phase 1a, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to the progress, future patient enrollment in and timing of our clinical trials and announcements of results thereof. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:8/1/2014)... 1, 2014 In the latest call for ... dysfunction, more than 60 doctors and leading medical experts ... questioning the Food and Drug Administration,s (FDA) decision to ... of male sexual dysfunction compared with ZERO for women,s ... act for women by approving the first-ever drug to ...
(Date:8/1/2014)... 2014 In the latest call for gender ... more than 60 doctors and leading medical experts from ... the Food and Drug Administration,s (FDA) decision to approve ... male sexual dysfunction compared with ZERO for women,s most ... for women by approving the first-ever drug to treat ...
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it ... This designation recognizes Aspire for delivering outstanding customer service to ... . "Achieving exceptional results for our customers is ... President and CEO of Aspire. "We are pleased Cisco has ... award and are proud to be part of the Cisco ...
Breaking Medicine Technology:60+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2
... May 3, 2012 /PRNewswire-Asia/ -- Johnson & ... has acquired Guangzhou Bioseal Biotechnology Co., Ltd. ... in the design, development and commercialization of ... bleeding during surgery. The acquisition was completed ...
... Cochlear Americas , the world,s leading implantable hearing ... smartphone support application for Nucleus® Cochlear Implant recipients. ... App as part of Cochlear,s mobile support initiative, ... and wherever they need it. (Photo: ...
Cached Medicine Technology:Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd. 2Cochlear™ Americas Adds the Nucleus® Support App to its Mobile Service Offerings 2
(Date:8/1/2014)... Medicine in St. Louis helps explain why brain tumors ... harmful than similar tumors in females. For example, glioblastomas, ... as often in males, who suffer greater cognitive impairments ... The researchers found that retinoblastoma protein (RB), a protein ... in male brain cells than in female brain cells. ...
(Date:8/1/2014)... News) -- The U.S. Food and Drug Administration announced ... to help fight type 2 diabetes. Jardiance ... treatment regimens to control blood sugar levels in the ... the Office of Drug Evaluation II in the FDA,s ... agency statement. The FDA also recommended that Jardiance ...
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
(Date:8/1/2014)... News) -- Patients with the progressive, deadly respiratory ailment ... new weapon to battle the disease, the U.S. Food ... approved a new treatment, an inhaled spray called Striverdi ... Americans. COPD, which is often linked to smoking, involves ... Patients with COPD may experience a number ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... industrial chemicals in the environment can damage the developing ... deficit disorder (ADHD), and mental retardation. Still, there has ... that can cause injury to the developing brains of ... in the print issue of The Lancet researchers from ...
... 47-year-old woman who lost her hands in a chemical explosion some ... This is the first of its kind done in Spain, and ... the Pedro Cavadas Foundation performed this ten- hour operation. ... and may be released from hospital next week and should get ...
... US HIV/AIDS healthcare provider will soon be reaching out ... Assam to provide treatment and support//. ,The US-based ... counselling and testing centres in Assam's main city of ... city of Silchar. ,India's National AIDS ...
... with yet another significant product from soybean. A study ... made from soy has amazing restorative powers. ... Jefferson Medical College found that giving doses of a ... animals’ ability to move and walk. ,Over ...
... the senior citizens have become sensitive to health issues, and ... under control. ,Study author, Bernard M.Y. Cheung, said,"It ... We have tried to see if the explanation lies in ... increase in these, so probably all of these contribute in ...
... now be made more easily available to critically ill patients. ... that will enable patients// who are extremely ill to try ... options. ,The FDA has announced that they will ... to be made available to needy individuals .They will also ...
Cached Medicine News:Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:US NGO to Counsel HIV/AIDS Patients in Assam 2Health News:Soy’s Restorative Powers Confirme 2
The Hilan pneumatic high speed drill system consists of a pneumatic motor and drill with various cutting attachments....
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
... The Ruggles Retractor System, a ... and the versatility of two systems ... hands from the surgical site during ... accurate retractor insertion. The retractor body ...
Medicine Products: